BMP-7 attenuates left ventricular remodelling under pressure overload and facilitates reverse remodelling and functional recovery

Cardiovascular Research

Volumn 110, Issue 3, 2016, Pages 331-345

  Merino, David ^a,b   Villar, Ana V ^a,b   García, Raquel ^a,b   Tramullas, Mónica ^a,b   Ruiz, Luis ^b,c   Ribas, Catalina ^d,e   Cabezudo, Sofía ^d,e   Nistal, Juan Francisco ^b,c   Hurlé, María A ^a,b  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b IFIMAV   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

Author keywords

Aortic stenosis; BMP 7; Myocardial remodelling; Pressure overload; Reverse remodelling; TGF

Indexed keywords

COLLAGEN; CYTOKINE; FIBRONECTIN; NEUTRALIZING ANTIBODY; OSTEOGENIC PROTEIN 1; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; BMP7 PROTEIN, HUMAN; BMP7 PROTEIN, MOUSE; MYOSIN HEAVY CHAIN; RECOMBINANT PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; AORTA STENOSIS; ARTICLE; CARDIAC MUSCLE CELL; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FEMALE; FIBROBLAST; GENE DELETION; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE BIOPSY; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; IMMUNOBLOTTING; MAJOR HISTOCOMPATIBILITY COMPLEX; MORPHOLOGY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; AGED; ANIMAL; AORTIC VALVE STENOSIS; C57BL MOUSE; CASE CONTROL STUDY; COMPLICATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENETICS; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTROPHY, LEFT VENTRICULAR; KNOCKOUT MOUSE; MALE; METABOLISM; MIDDLE AGED; NIH 3T3 CELL LINE; PATHOLOGY; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; SIGNAL TRANSDUCTION; TIME FACTOR; VERY ELDERLY; WISTAR RAT;

AGED; AGED, 80 AND OVER; ANIMALS; AORTIC VALVE STENOSIS; BONE MORPHOGENETIC PROTEIN 7; CASE-CONTROL STUDIES; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FIBRONECTINS; FIBROSIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MYOCYTES, CARDIAC; MYOSIN HEAVY CHAINS; NIH 3T3 CELLS; RATS, WISTAR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84973392541     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw076     Document Type: Article

References (47)

1. Iung B, Baron G, Tornos P, Gohlke-Bärwolf C, Butchart EG, Vahanian A. Valvular heart disease in the community: a European experience. Curr Probl Cardiol 2007;32:609-661.
2. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodelling: mechanisms: part 1 of 2. Circulation 2013;128:388-400.
3. Grossman W, Paulus WJ. Myocardial stress and hypertrophy: a complex interface between biophysics and cardiac remodelling. J Clin Invest 2013;123:3701-3703.
4. Lund O, Emmertsen K, Dørup I, Jensen FT, Flø C. Regression of left ventricular hypertrophy during 10 years after valve replacement for aortic stenosis is related to the preoperative risk profile. Eur Heart J 2003;24:1437-1446.
5. Villar AV, Merino D, Wenner M, Llano M, Cobo M, Montalvo C, García R, Martín-Durán R, HurléJM, HurléMA, Nistal JF. Myocardial gene expression of microRNA-133a and myosin heavy and light chains, in conjunction with clinical parameters, predict regression of left ventricular hypertrophy after valve replacement in patients with aortic stenosis. Heart 2011;97:1132-1137.
6. Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 1989;79:744-755.
7. Weidemann F, Herrmann S, Störk S, Niemann M, Frantz S, Lange V, Beer M, Gattenlöhner S, VoelkerW, Ertl G, Strotmann JM. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009;120:577-584.
8. MassaguéJ. TGFb signalling in context. Nat Rev Mol Cell Biol 2012;13:616-630.
9. Yan X, Chen YG. Smad7: not only a regulator, but also a cross-talk mediator of TGF-b signalling. Biochem J 2011;434:1-10.
10. Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, Kanzler S, Geier A, Breitkopf K,Weng H, Mertens PR. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 2008;135:642-659.
11. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13:952-961.
12. Villar AV, Cobo M, Llano M, Montalvo C, González-Vílchez F, Martín-Durán R, HurléMA, Nistal JF. Plasma levels of transforming growth factor-beta1 reflect left ventricular remodelling in aortic stenosis. PLoS One 2009;4:e8476.
13. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-b signallingin cardiac remodelling. J Mol Cell Cardiol 2011;51:600-606.
14. Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang D, Nakamura T, Takimoto E, Kass DA. Pivotal role of cardiomyocyte TGF-b signallingin the murine pathological response to sustained pressure overload. J Clin Invest 2011;121: 2301-2312.
15. Montalvo C, Villar AV, Merino D, García R, Ares M, Llano M, Cobo M, HurléMA, Nistal JF. Androgens contribute to sex differences in myocardial remodelling under pressure overload by a mechanism involving TGF-b. PLoS One 2012;7:e35635.
16. Villar AV, García R, Llano M, Cobo M, Merino D, Lantero A, Tramullas M, HurléJM, HurléMA, Nistal JF. BAMBI (BMP and activin membrane-bound inhibitor) protects the murine heart from pressure-overload biomechanical stress by restraining TGF-b signaling. Biochim Biophys Acta Mol Basis Dis 2013;1832:323-335.
17. Beaumont J, López B, Hermida N, Schroen B, San JoséG, Heymans S, Valencia F, Gómez-Doblas JJ, De Teresa E, Díez J, González A. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-b1 up-regulation. Clin Sci (Lond) 2014;126:497-506.
18. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003;9:964-968.
19. Weiskirchen R, Meurer SK. BMP-7 counteracting TGF-beta1 activities in organ fibrosis. Front Biosci 2013;18:1407-1434.
20. Watkins SJ, Borthwick GM, Arthur HM. The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev Biol Anim 2011;47:125-131.
21. Wang LP, Dong JZ, Xiong LJ, Shi KQ, Zou ZL, Zhang SN, Cao ST, Lin Z, Chen YP. BMP-7 attenuates liver fibrosis via regulation of epidermal growth factor receptor. Int J Clin Exp Pathol 2014;7:3537-3547.
22. Morrissey J, Hruska K, Guo G, Wang S, Chen Q, Klahr S. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 2002;13:S14-S21.
23. Sugimoto H, Yang C, LeBleu VS, Soubasakos MA, Giraldo M, Zeisberg M, Kalluri R. BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J 2007;21: 256-264.
24. Urbina P, Singla DK. BMP-7 attenuates adverse cardiac remodelling mediated through M2 macrophages in prediabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2014; 307:H762-H772.
25. Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006;17: 2504-2512.
26. Kinoshita K, Iimuro Y, Otogawa K, Saika S, Inagaki Y, Nakajima Y, Kawada N, Fujimoto J, Friedman SL, Ikeda K. Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut 2007;56:706-714.
27. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, Carlson W Jr, Bey P, Rusckowski M, Tampe B, Tampe D, Kanasaki K, Zeisberg M, Kalluri R. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 2012;18:396-404.
28. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 2002;282:H1685-H1696.
29. Pegorier S, Campbell GA, Kay AB, Lloyd CM. Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-beta1 in normal human lung fibroblasts (NHLF). Respir Res 2010;11:85.
30. Wang S, Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem 2004;279:23200-23206.
31. Midgley AC, Duggal L, Jenkins R, Hascall V, Steadman R, Phillips AO, Meran S. Hyaluronan regulates Bone Morphogenetic Protein-7 dependent prevention and reversal of myofibroblast phenotype. J Biol Chem 2015;290:11218-11234.
32. Cohn JN, Ferrari R, Sharpe NR. Cardiac remodelling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodelling. Behalf of an International Forum on Cardiac Remodelling. J Am Coll Cardiol 2000;35:569-582.
33. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, Schlüter KD, Böhm M. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002;283: H1253-H1262.
34. Cartledge JE, Kane C, Dias P, Tesfom M, Clarke L, Mckee B, Al Ayoubi S, Chester A, Yacoub MH, Camelliti P, Terracciano CM. Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovasc Res 2015;105: 260-270.
35. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
36. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000;102:470-479.
37. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 2005;289:H8-H16.
38. Ali A, Patel A, Ali Z, Abu-Omar Y, Saeed A, Athanasiou T, Pepper J. Enhanced left ventricular mass regression after aortic valve replacement in patients with aortic stenosis is associated with improved long-term survival. J Thorac Cardiovasc Surg 2011;142: 285-291.
39. Schultheiss TM, Burch JB, Lassar AB. A role for bone morphogenetic proteins in the induction of cardiac myogenesis. Genes Dev 1997;11:451-462.
40. Wu X, Sagave J, Rutkovskiy A, Haugen F, Baysa A, Nygard S, Czibik G, Dahl CP, Gullestad L, Vaage J, Valen G. Expression of bone morphogenetic protein 4 and its receptors in the remodelling heart. Life Sci 2014;97:145-154.
41. DornGWII, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res 2003;92:1171-1175.
42. Benchabane H, Wrana JL. GATA-and Smad1-dependent enhancers in the Smad7 gene differentially interpret bone morphogenetic protein concentrations. Mol Cell Biol 2003; 23:6646-6661.
43. Wei LH, Huang XR, Zhang Y, Li YQ, Chen HY, Yan BP, Yu CM, Lan HY. Smad7 inhibits angiotensin II-induced hypertensive cardiac remodelling. Cardiovasc Res 2013;99: 665-673.
44. Gao XM, Kiriazis H, Moore XL, Feng XH, Sheppard K, Dart A, Du XJ. Regression of pressure overload-induced left ventricular hypertrophy in mice. Am J Physiol Heart Circ Physiol 2005;288:H2702-H2707.
45. Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol 2012;60:2465-2472.
46. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014;57:660-671.
47. Godin RE, Takaesu NT, Robertson EJ, Dudley AT. Regulation of BMP7 expression during kidney development. Development 1998;125:3473-3482.